AU2020243073B2 - Recombinant CCN domain proteins and fusion proteins - Google Patents

Recombinant CCN domain proteins and fusion proteins Download PDF

Info

Publication number
AU2020243073B2
AU2020243073B2 AU2020243073A AU2020243073A AU2020243073B2 AU 2020243073 B2 AU2020243073 B2 AU 2020243073B2 AU 2020243073 A AU2020243073 A AU 2020243073A AU 2020243073 A AU2020243073 A AU 2020243073A AU 2020243073 B2 AU2020243073 B2 AU 2020243073B2
Authority
AU
Australia
Prior art keywords
seq
protein
ser
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020243073A
Other languages
English (en)
Other versions
AU2020243073A1 (en
Inventor
Håvard Attramadal
Ole Jørgen KAASBØLL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oslo University Hospital
Original Assignee
Oslo University Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo University Hospital filed Critical Oslo University Hospital
Publication of AU2020243073A1 publication Critical patent/AU2020243073A1/en
Application granted granted Critical
Publication of AU2020243073B2 publication Critical patent/AU2020243073B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020243073A 2019-03-20 2020-03-20 Recombinant CCN domain proteins and fusion proteins Active AU2020243073B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19163970.7 2019-03-20
EP19163970.7A EP3711772A1 (en) 2019-03-20 2019-03-20 Recombinant proteins and fusion proteins
PCT/EP2020/057773 WO2020188081A1 (en) 2019-03-20 2020-03-20 Recombinant ccn domain proteins and fusion proteins

Publications (2)

Publication Number Publication Date
AU2020243073A1 AU2020243073A1 (en) 2021-11-11
AU2020243073B2 true AU2020243073B2 (en) 2025-06-05

Family

ID=66102364

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020243073A Active AU2020243073B2 (en) 2019-03-20 2020-03-20 Recombinant CCN domain proteins and fusion proteins

Country Status (12)

Country Link
US (2) US12606602B2 (cg-RX-API-DMAC7.html)
EP (2) EP3711772A1 (cg-RX-API-DMAC7.html)
JP (1) JP7600135B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210142681A (cg-RX-API-DMAC7.html)
CN (1) CN113747912B (cg-RX-API-DMAC7.html)
AU (1) AU2020243073B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017147A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133740A1 (cg-RX-API-DMAC7.html)
IL (1) IL285930B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021011407A (cg-RX-API-DMAC7.html)
SG (1) SG11202109738QA (cg-RX-API-DMAC7.html)
WO (1) WO2020188081A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240043544A1 (en) * 2020-12-08 2024-02-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-egfr chimeric antigen receptors
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
GB202400055D0 (en) * 2024-01-03 2024-02-14 Tribune Therapeutics Ab Use of ccn domain-containing proteins for the treatment of disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2858234A1 (fr) * 2003-08-01 2005-02-04 Centre Nat Rech Scient Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1999047556A2 (en) * 1998-03-19 1999-09-23 Trustees Of Tufts College Novel heparin-induced ccn-like molecules and uses therefor
AU2437702A (en) * 2000-10-16 2002-04-29 Genentech Inc Methods of treatment using wisp polypeptides
CN1835763B (zh) 2003-06-20 2011-04-20 妙甯公司 Ccn1组合物和方法
MX2007001180A (es) 2004-07-26 2007-04-13 Asterion Ltd Enlazantes.
AU2006203851B8 (en) 2005-01-10 2012-11-15 Rosalind Franklin University Of Medicine And Science Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
CA2591914C (en) 2005-01-24 2017-04-25 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
JP2009512423A (ja) * 2005-09-12 2009-03-26 ザ・ジョンズ・ホプキンス・ユニバーシティ 抗血管新生の活性を有する組成物及びその使用
JP2009067678A (ja) * 2005-12-07 2009-04-02 Nihon Nosan Kogyo Kk 結合組織増殖因子に対する抗体又はそれを含む組成物
US20080207489A1 (en) 2007-02-21 2008-08-28 John Castellot Use of CCN5 for treatment of smooth muscle proliferation disorders
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
CN102421893B (zh) 2009-04-30 2014-10-29 花王株式会社 碱性蛋白酶变体
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
CA2773737C (en) 2009-09-09 2021-11-16 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
KR101187814B1 (ko) 2010-03-22 2012-10-08 광주과학기술원 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
US9114112B2 (en) 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
JP5939584B2 (ja) 2010-04-02 2016-06-22 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス 治療用ccn3ペプチドおよびそれらの類似体
MX349054B (es) * 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
SG191233A1 (en) 2010-12-23 2013-07-31 Janssen Biotech Inc Active protease-resistant antibody fc mutants
WO2014008582A1 (en) 2012-07-11 2014-01-16 The University Of Western Ontario Method of treating wounds with penostin and/or ccn2
US20140271641A1 (en) 2013-03-14 2014-09-18 University Of Guelph Thrombospondin-1 polypeptides and methods of using same
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
JP6862348B2 (ja) 2015-03-12 2021-04-21 メディミューン,エルエルシー アルブミン融合タンパク質を精製する方法
JP2018517708A (ja) * 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1(Cyr61)在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
EP3192806A1 (en) 2016-01-13 2017-07-19 Affiris AG Alpha chain of the high-affinity ige receptor (fceria)
CN109071631B (zh) 2016-03-14 2023-07-14 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
WO2018026283A1 (en) 2016-08-04 2018-02-08 Stichting Vumc Embryonic angiogenesis markers and diagnostic and therapeutic strategies based thereon
US20180127478A1 (en) 2016-09-16 2018-05-10 Wei-Chiang Shen SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY
KR20180099537A (ko) * 2017-02-28 2018-09-05 주식회사 파이안바이오테크놀로지 근섬유모세포의 병리적 활성이 초래하는 섬유증식성 질병 치료제
KR102008407B1 (ko) 2017-09-05 2019-08-08 한국생명공학연구원 코돈 최적화된 il-21 및 이의 용도
US20190105340A1 (en) 2017-10-05 2019-04-11 New York Genome Center, Inc. Methods and compositions for targeting vascular mimicry

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2858234A1 (fr) * 2003-08-01 2005-02-04 Centre Nat Rech Scient Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OLE JØRGEN KAASBØLL ET AL: "Connective tissue growth factor (CCN2) is a matricellular preproprotein controlled by proteolytic activation", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 293, no. 46, 16 November 2018 pages 17953 - 17970 *

Also Published As

Publication number Publication date
AU2020243073A1 (en) 2021-11-11
IL285930A (en) 2021-10-31
US20260167686A1 (en) 2026-06-18
IL285930B1 (en) 2024-09-01
BR112021017147A2 (pt) 2021-11-09
US20220144903A1 (en) 2022-05-12
EP3711772A1 (en) 2020-09-23
JP7600135B2 (ja) 2024-12-16
US12606602B2 (en) 2026-04-21
CN113747912A (zh) 2021-12-03
SG11202109738QA (en) 2021-10-28
MX2021011407A (es) 2022-01-24
CN113747912B (zh) 2025-04-04
JP2022525661A (ja) 2022-05-18
IL285930B2 (en) 2025-01-01
EP3941507A1 (en) 2022-01-26
KR20210142681A (ko) 2021-11-25
CA3133740A1 (en) 2020-09-24
WO2020188081A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
CN103732628B (zh) 多价杂多聚体骨架设计和构建体
EP2858662B1 (en) Fibroblast growth factor 21 proteins
KR101808751B1 (ko) 폰 빌레브란트 인자(vWF)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
AU2014296107B2 (en) Growth differentiation factor 15 (GDF-15) constructs
KR100467751B1 (ko) 생체내 에리스로포이에틴 활성이 증진된 융합단백질
JP2634323B2 (ja) Tcf‐▲ii▼のアミノ酸配列をコードするdnaを含むプラスミド,形質転換細胞及びこれを用いて生理活性物質を生産する方法
KR20240027854A (ko) Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도
JP2017528419A (ja) Mic−1融合タンパク質及びその使用
EP3060235B1 (en) Endoglin peptides to treat fibrotic diseases
US20220048981A1 (en) Modified product of fc domain of antibody
US12606602B2 (en) Recombinant CCN domain proteins and fusion proteins
CN114591415A (zh) Glp-1/gcg双受体激动剂多肽及其融合蛋白
CN112028985A (zh) 基因工程生长因子变异体
KR20140093942A (ko) 인간 노치1 디코이
US20170334971A1 (en) Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки
EP2162463B1 (en) Vegf-d mutants and their use
US20220348623A1 (en) Stabilized proteolytically activated growth differentiation factor 11
KR20220006013A (ko) 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도
CN115873127B (zh) 重组长效人生长激素融合蛋白及其制备方法和用途
HK1228288A1 (en) Endoglin peptides to treat fibrotic diseases
HK1228288B (en) Endoglin peptides to treat fibrotic diseases
EA046387B1 (ru) Конструкции на основе фактора дифференцировки и роста 15 (gdf15)
KR20090030497A (ko) 핵 이동 신호 펩타이드 및 이를 이용하여 이종 단백질을핵으로 이동시키는 방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)